57 min
Unlocking the Potential of Genetic Medicines Bioverge
-
- Business
David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.
David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.
57 min